Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06959511 · ClinicalTrials.gov registry record · Phase 2
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
A Phase 2 study of Thyroid Cancer and Neoadjuvant Treatment, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT06959511: Recruiting Phase 2 study of Thyroid Cancer and Neoadjuvant Treatment, sponsored by M.D. Anderson Cancer Center.
NCT06959511 is a Phase 2 study of Thyroid Cancer and Neoadjuvant Treatment that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 45 participants, below the 281-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06959511, a Phase 2 study of Thyroid Cancer and Neoadjuvant Treatment, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
To look at the effectiveness of zanzalintinib, followed by surgery, in treating advanced thyroid cancer. The safety of this treatment will also be studied.
Primary Outcome
Defined as the proportion of patients who have a MR, PR, or CR per modified RECIST 1.1. CR and PR are defined using the same criteria as in RECIST 1.1. MR is defined as a 15% or greater decrease in the sum of the longest diameters of target lesions but not a PR. The MR+PR+CR response rate will be determined by dividing the number of patients with modified RECIST-based MR, PR, or CR divided by the number of evaluable patients
Conditions Studied
Interventions
- DRUG Zanzalintinib
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-07-22 |
| Est. Completion | 2030-10-01 |
| Phase | Phase 2 |
What NCT06959511 shows while recruiting
NCT06959511 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 281-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (84% lower).
The record links to 2 conditions, with Thyroid Cancer appearing as the primary indexed condition, and to 1 intervention - of which Zanzalintinib is the first listed.
NCT06959511 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06959511 about?
NCT06959511 is a clinical study titled "Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery". To look at the effectiveness of zanzalintinib, followed by surgery, in treating advanced thyroid cancer. The safety of this treatment will also be studied.
What is the current status of trial NCT06959511?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2025-07-22. Estimated completion is 2030-10-01.
What conditions does trial NCT06959511 study?
This clinical trial studies the following conditions: Thyroid Cancer, Neoadjuvant Treatment.
What interventions are being tested in trial NCT06959511?
The interventions under investigation include: Zanzalintinib (DRUG).
Who is sponsoring clinical trial NCT06959511?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06959511 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06959511's enrollment target sits among peer trials
45 27th of 46 higher than 20 of 46 other Thyroid Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thyroid Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
RECRUITING · Phase 2
-
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
RECRUITING · Phase 2
-
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
RECRUITING · Phase 2
-
Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer
RECRUITING · Phase 2
-
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
RECRUITING · Phase 2
-
Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI